In the US, BEXSERO is indicated for active immunization to prevent invasive disease caused byNeisseria meningitidisserogroup B in individuals from 10 through 25 years. Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activi...
Shingrix Trelegy Nucala Bexsero Arexvy Twinrix Resources Information for your practice Resources for your practice We’re dedicated to helping you and your patients with information and support through the offerings below. Information for your practice Get helpful information to help you in your...
Menveo Bexsero SotrovimabMenveo® pregnancy registry: an observational study on the safety of Menveo exposure in pregnant women and their offspring Menveo® pregnancy registry is established to meet a post marketing commitment agreed upon with CBER to establish a pregnancy registry to prospectively...
In June, the European Medicines Agency approved a new, alternative (2+1) dosing schedule for Bexsero in infants (in addition to the existing 3+1 schedule), offering healthcare professionals more options to help protect infants from invasive meningococcal disease (IMD) caused by serogroup B and ...
After months of delay, GlaxoSmithKline has agreed a deal with the UK government that will allow its meningitis B (MenB) vaccine Bexsero to be added to the NHS' routine childhood immunisation schedule. The agreement on pricing has not been revealed...Andrew McConaghie...
the original source of Ventolin Nebule. This shutdown resulted in stockpiling the necessary quantities until products from the new site became available. However, increased domestic demand and delays in the supply schedule following a change in the license for the new site accelerated the depletion ...
After months of delay, GlaxoSmithKline has agreed a deal with the UK government that will allow its meningitis B (MenB) vaccine Bexsero to be added to the NHS' routine childhood immunisation schedule. The agreement on pricing has not been revealed...Andrew McConaghie...